Johnson Investment Counsel Inc. Decreases Holdings in Sanofi (NASDAQ:SNY)

Johnson Investment Counsel Inc. cut its holdings in shares of Sanofi (NASDAQ:SNY) by 4.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,846 shares of the company’s stock after selling 701 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Sanofi were worth $668,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in SNY. Raymond James Financial Inc. purchased a new stake in Sanofi in the 4th quarter worth about $135,933,000. Jennison Associates LLC increased its holdings in Sanofi by 938.0% in the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after acquiring an additional 1,720,972 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in Sanofi by 28,890.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock worth $82,366,000 after acquiring an additional 1,424,289 shares during the last quarter. DAVENPORT & Co LLC increased its holdings in Sanofi by 40.7% in the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after acquiring an additional 664,455 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after acquiring an additional 399,301 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on SNY shares. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Sanofi has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Stock Down 1.8 %

SNY stock opened at $57.69 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $146.41 billion, a PE ratio of 23.17, a PEG ratio of 1.01 and a beta of 0.58. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The stock has a 50-day simple moving average of $53.27 and a two-hundred day simple moving average of $52.81.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, equities analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.